In the present study, experiments were performed to investigate whether LATS2 could attenuate sorafenib-mediated therapeutic resistance in HCC via modulating mitophagy in a manner dependent on the AMPK/MFN2 pathway. This evidence concerns the gene LATS2 and hepatocellular carcinoma.